<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01869764</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00023419</org_study_id>
    <secondary_id>NCI-2013-00963</secondary_id>
    <secondary_id>P30CA012197</secondary_id>
    <secondary_id>CCCWFU 98113</secondary_id>
    <nct_id>NCT01869764</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer</brief_title>
  <official_title>A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II clinical trial studies how well omega-3 fatty acid works in treating patients
      with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from
      breast cancer patients receiving omega-3 fatty acid may help doctors learn more about the
      effects of omega-3 fatty acid on tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if omega-3 dietary supplementation (omega-3 fatty acid) results in higher
      polyunsaturated fatty acids (PUFA) levels in surgical specimens of normal and malignant
      breast tissue in women who took omega 3 tablets in comparison to those who took placebo.

      II. To determine if omega-3 dietary supplementation results in higher PUFA levels in plasma
      and red blood cells in women who took omega 3 tablets in comparison to those who took
      placebo.

      III. To determine if omega-3 dietary supplementation affects the metabolites of omega-3 and
      omega-6 PUFA in surgical specimens of malignant and normal breast tissue in comparison to
      controls.

      IV. To determine if women who take omega-3 dietary supplementation have less proliferation
      and greater apoptosis in malignant breast tissue in comparison to women who take placebo.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive omega-3 fatty acid orally (PO) daily for 7-14 days.

      ARM II: Patients receive placebo PO daily for 7-14 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PUFA Levels in Normal and Metastatic Breast Tissue</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PUFA Levels in Plasma Pre and Post Surgery</measure>
    <time_frame>Pre and post surgery</time_frame>
    <description>Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PUFA Levels in Red Blood Cells Pre and Post Surgery</measure>
    <time_frame>Pre and post surgery</time_frame>
    <description>Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolites of Omega-3 and Omega-6 PUFA in Malignant and Normal Breast Tissue</measure>
    <time_frame>At time of surgery</time_frame>
    <description>ANOVA will be used to assess the effect in normal and malignant breast tissue. Metabolites tested: PGE2, PGD2, 20-HETE, 5-HEPE, 13-HODE, 9-HODE, 15-HETE, 12-HETE, 5-HETE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days to Establish Difference in Proliferation in Malignant Breast Tissue</measure>
    <time_frame>At time of surgery</time_frame>
    <description>ANOVA will be used to assess the effect of the supplementation in malignant breast tissue with less proliferation in malignant breast tissue in comparison to women who took the placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days to Establish Increased Apoptosis in Malignant Breast Tissue</measure>
    <time_frame>At time of surgery</time_frame>
    <description>ANOVA will be used to assess the effect of the supplementation in malignant breast tissue with greater apoptosis in malignant breast tissue in comparison to women who took the placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Ductal Breast Carcinoma in Situ</condition>
  <condition>Lobular Breast Carcinoma in Situ</condition>
  <condition>Male Breast Cancer</condition>
  <condition>Stage IA Breast Cancer</condition>
  <condition>Stage IB Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (omega-3 fatty acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive omega-3 fatty acid PO daily for 7-14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO daily for 7-14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 fatty acid</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (omega-3 fatty acid)</arm_group_label>
    <other_name>fish oil</other_name>
    <other_name>n-3 fatty acid</other_name>
    <other_name>O3FA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (omega-3 fatty acid)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed stage I to III breast cancer and carcinoma in situ (including lobular
             carcinoma in situ [LCIS] and ductal carcinoma in situ [DCIS])

          -  Breast surgery (lumpectomy or mastectomy) is planned for at least 7 days from the day
             of enrollment

          -  Ability to understand and the willingness to sign an Institutional Review Board
             (IRB)-approved written informed consent document

          -  Tumor measures at least 1 centimeter on imaging or physical exam

        Exclusion Criteria:

          -  Any patient with surgery scheduled &lt; 7days after biopsy

          -  Patients who are unable to refrain from the use of any NSAID or full-dose
             acetylsalicylic acid (ASA)-containing NSAID while taking study drug

          -  Patients who will receive neoadjuvant chemotherapy are not eligible

          -  Patients who are currently taking omega-3 fatty acids, as they are unable to be
             randomized to placebo

          -  Patients who have previously taken omega-3 fatty acid within 1 month prior to study
             enrollment

          -  Patients with an allergy or known hypersensitivity to fish
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 31, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <results_first_submitted>August 1, 2019</results_first_submitted>
  <results_first_submitted_qc>October 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2019</results_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
    <mesh_term>Carcinoma, Lobular</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 24, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT01869764/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT01869764/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Omega-3 Fatty Acid)</title>
          <description>Patients receive omega-3 fatty acid PO daily for 7-14 days.
omega-3 fatty acid: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO daily for 7-14 days.
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Omega-3 Fatty Acid)</title>
          <description>Patients receive omega-3 fatty acid PO daily for 7-14 days.
omega-3 fatty acid: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO daily for 7-14 days.
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="14.0"/>
                    <measurement group_id="B2" value="59.9" spread="9.5"/>
                    <measurement group_id="B3" value="58.8" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PUFA Levels in Normal and Metastatic Breast Tissue</title>
        <description>Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3</description>
        <time_frame>At time of surgery</time_frame>
        <population>All samples measurements were not available for all participants to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Omega-3 Fatty Acid)</title>
            <description>Patients receive omega-3 fatty acid PO daily for 7-14 days.
omega-3 fatty acid: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO daily for 7-14 days.
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>PUFA Levels in Normal and Metastatic Breast Tissue</title>
          <description>Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3</description>
          <population>All samples measurements were not available for all participants to be analyzed.</population>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal breast tissue 18:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.986" spread="40.392"/>
                    <measurement group_id="O2" value="72.762" spread="50.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 18:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.232" spread="2.289"/>
                    <measurement group_id="O2" value="3.505" spread="2.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 20:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.104" spread="0.96"/>
                    <measurement group_id="O2" value="1.008" spread="0.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 20:4 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.221" spread="1.349"/>
                    <measurement group_id="O2" value="2.342" spread="1.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 20:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" spread="0.107"/>
                    <measurement group_id="O2" value="0.038" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 20:5 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="0.128"/>
                    <measurement group_id="O2" value="0.034" spread="0.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 22:6 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.095" spread="0.443"/>
                    <measurement group_id="O2" value="0.061" spread="0.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.402" spread="2.572"/>
                    <measurement group_id="O2" value="3.64" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.421" spread="2.085"/>
                    <measurement group_id="O2" value="3.413" spread="1.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue n3/n-6 ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.948" spread="0.468"/>
                    <measurement group_id="O2" value="1.102" spread="0.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast tissue 18:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.137" spread="44.544"/>
                    <measurement group_id="O2" value="33.735" spread="31.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast 18:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.943" spread="2.162"/>
                    <measurement group_id="O2" value="1.356" spread="1.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast 20:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.889" spread="0.886"/>
                    <measurement group_id="O2" value="0.601" spread="0.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast 20:4 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.208" spread="1.948"/>
                    <measurement group_id="O2" value="2.248" spread="1.744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast 20:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.087"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast 20:5 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.665"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast 22:6 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.178" spread="2.41"/>
                    <measurement group_id="O2" value="1.357" spread="1.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.233" spread="46.105"/>
                    <measurement group_id="O2" value="36.586" spread="32.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast n-3/n-6 ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" spread="0.031"/>
                    <measurement group_id="O2" value="0.032" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 18:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.85" spread="51.043"/>
                    <measurement group_id="O2" value="-39.027" spread="38.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 18:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.289" spread="2.784"/>
                    <measurement group_id="O2" value="-2.149" spread="1.935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.215" spread="0.866"/>
                    <measurement group_id="O2" value="-0.407" spread="0.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:4 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.986" spread="1.595"/>
                    <measurement group_id="O2" value="-0.094" spread="1.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" spread="0.105"/>
                    <measurement group_id="O2" value="-0.038" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:5 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.173" spread="0.545"/>
                    <measurement group_id="O2" value="-0.034" spread="0.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 22:6 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.095" spread="0.443"/>
                    <measurement group_id="O2" value="-0.061" spread="0.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in PUFA level n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.224" spread="2.794"/>
                    <measurement group_id="O2" value="-2.282" spread="2.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in PUFA level in n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.812" spread="45.463"/>
                    <measurement group_id="O2" value="33.173" spread="31.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in n-3/n-6 ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.45"/>
                    <measurement group_id="O2" value="-1.07" spread="0.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PUFA Levels in Plasma Pre and Post Surgery</title>
        <description>Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3</description>
        <time_frame>Pre and post surgery</time_frame>
        <population>All samples measurements were not available for all participants to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Omega-3 Fatty Acid)</title>
            <description>Patients receive omega-3 fatty acid PO daily for 7-14 days.
omega-3 fatty acid: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO daily for 7-14 days.
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>PUFA Levels in Plasma Pre and Post Surgery</title>
          <description>Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3</description>
          <population>All samples measurements were not available for all participants to be analyzed.</population>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma pre-surgery 18:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1514890" spread="370945"/>
                    <measurement group_id="O2" value="1539300" spread="370726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma pre-surgery 18:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37501" spread="25256"/>
                    <measurement group_id="O2" value="33119" spread="19368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma pre-surgery 20:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7039" spread="6213"/>
                    <measurement group_id="O2" value="6031" spread="5612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma pre-surgery 20:4 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210238" spread="77734"/>
                    <measurement group_id="O2" value="210006" spread="83260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma pre-surgery 20:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma pre-surgery 20:5 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38539" spread="30967"/>
                    <measurement group_id="O2" value="50206" spread="41170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma pre-surgery 22:6 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132887" spread="68619"/>
                    <measurement group_id="O2" value="111798" spread="79889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma pre-surgery n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208297" spread="105288"/>
                    <measurement group_id="O2" value="195123" spread="106007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma pre-surgery n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1732167" spread="373713"/>
                    <measurement group_id="O2" value="1755338" spread="397402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma pre-surgery n3/n-6 ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.121" spread="0.058"/>
                    <measurement group_id="O2" value="0.11" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma post-surgery 18:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1504732" spread="497732"/>
                    <measurement group_id="O2" value="1507750" spread="419001.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma post-surgery 18:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37472" spread="18521"/>
                    <measurement group_id="O2" value="34202.78" spread="15615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma post-surgery 20:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5980" spread="5351"/>
                    <measurement group_id="O2" value="6851.409" spread="5479.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma post-surgery 20:4 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168100" spread="63105"/>
                    <measurement group_id="O2" value="204127.2" spread="85101.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma post-surgery 20:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma post-surgery 20:5 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74521" spread="48954"/>
                    <measurement group_id="O2" value="52643.85" spread="32019.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma post-surgery 22:6 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153607" spread="83888"/>
                    <measurement group_id="O2" value="133832.8" spread="74361.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma post-surgery n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265600" spread="134862"/>
                    <measurement group_id="O2" value="220679.4" spread="108607.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma post-surgery n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1678812" spread="538264"/>
                    <measurement group_id="O2" value="1718729" spread="448393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma post-surgery n-3/n-6 ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.067"/>
                    <measurement group_id="O2" value="0.126" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 18:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23266" spread="602402"/>
                    <measurement group_id="O2" value="-34877" spread="365683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 18:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-554" spread="36051"/>
                    <measurement group_id="O2" value="1583" spread="20838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-824" spread="7018"/>
                    <measurement group_id="O2" value="485" spread="5683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:4 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37844" spread="87910"/>
                    <measurement group_id="O2" value="-8045" spread="69960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:5 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35551" spread="38628"/>
                    <measurement group_id="O2" value="2291" spread="25409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 22:6 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21487" spread="68743"/>
                    <measurement group_id="O2" value="19001" spread="72461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in PUFA level n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56484" spread="119807"/>
                    <measurement group_id="O2" value="22874" spread="83246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in PUFA level in n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61935" spread="653885"/>
                    <measurement group_id="O2" value="-42437" spread="414325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in n-3/n-6 ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.056"/>
                    <measurement group_id="O2" value="0.015" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PUFA Levels in Red Blood Cells Pre and Post Surgery</title>
        <description>Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3</description>
        <time_frame>Pre and post surgery</time_frame>
        <population>All samples measurements were not available for all participants to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Omega-3 Fatty Acid)</title>
            <description>Patients receive omega-3 fatty acid PO daily for 7-14 days.
omega-3 fatty acid: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO daily for 7-14 days.
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>PUFA Levels in Red Blood Cells Pre and Post Surgery</title>
          <description>Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3</description>
          <population>All samples measurements were not available for all participants to be analyzed.</population>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red blood cells pre-surgery 18:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351125" spread="130630"/>
                    <measurement group_id="O2" value="387455" spread="119089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells pre-surgery 18:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3430" spread="4505"/>
                    <measurement group_id="O2" value="3211" spread="4026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells pre-surgery 20:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2826" spread="3515"/>
                    <measurement group_id="O2" value="4014" spread="4183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells pre-surgeryy 20:4 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132624" spread="68691"/>
                    <measurement group_id="O2" value="144208" spread="71426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells pre-surgery 20:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells pre-surgery 20:5 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9723" spread="13112"/>
                    <measurement group_id="O2" value="11005" spread="14840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells pre-surgery 22:6 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79934" spread="77518"/>
                    <measurement group_id="O2" value="90668" spread="74168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells pre-surgery n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells pre-surgery n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells pre-surgery n3/n-6 ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells post-surgery 18:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391882" spread="183779"/>
                    <measurement group_id="O2" value="373679" spread="103361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells post-surgery 18:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5320" spread="4709"/>
                    <measurement group_id="O2" value="2103" spread="5007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells post-surgery 20:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3922" spread="3941"/>
                    <measurement group_id="O2" value="1842" spread="3315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells post-surgery 20:4 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149267" spread="70598"/>
                    <measurement group_id="O2" value="116868" spread="73523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells post-surgery 20:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells post-surgery 20:5 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25301" spread="29112"/>
                    <measurement group_id="O2" value="9818" spread="20929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells post-surgery 22:6 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110198" spread="90038"/>
                    <measurement group_id="O2" value="64117" spread="96118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells post-surgery n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells post-surgery n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cells post-surgery n-3/n-6 ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 18:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35856" spread="213680"/>
                    <measurement group_id="O2" value="-13776" spread="134998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 18:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1709" spread="4746"/>
                    <measurement group_id="O2" value="-1109" spread="5750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:2 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="948" spread="3481"/>
                    <measurement group_id="O2" value="-2172" spread="5204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:4 n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23282" spread="94096"/>
                    <measurement group_id="O2" value="-27340" spread="117792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:3 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 20:5 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15066" spread="29266"/>
                    <measurement group_id="O2" value="-1187" spread="28583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differences in PUFA level 22:6 n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42086" spread="101629"/>
                    <measurement group_id="O2" value="-26551" spread="128776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in PUFA level n-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in PUFA level in n-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in n-3/n-6 ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolites of Omega-3 and Omega-6 PUFA in Malignant and Normal Breast Tissue</title>
        <description>ANOVA will be used to assess the effect in normal and malignant breast tissue. Metabolites tested: PGE2, PGD2, 20-HETE, 5-HEPE, 13-HODE, 9-HODE, 15-HETE, 12-HETE, 5-HETE.</description>
        <time_frame>At time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Omega-3 Fatty Acid)</title>
            <description>Patients receive omega-3 fatty acid PO daily for 7-14 days.
omega-3 fatty acid: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO daily for 7-14 days.
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolites of Omega-3 and Omega-6 PUFA in Malignant and Normal Breast Tissue</title>
          <description>ANOVA will be used to assess the effect in normal and malignant breast tissue. Metabolites tested: PGE2, PGD2, 20-HETE, 5-HEPE, 13-HODE, 9-HODE, 15-HETE, 12-HETE, 5-HETE.</description>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal breast tissue PGE2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.14" spread="24.59"/>
                    <measurement group_id="O2" value="1.12" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue PGD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" spread="16.17"/>
                    <measurement group_id="O2" value="2.27" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 20HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="6.87"/>
                    <measurement group_id="O2" value="4.24" spread="18.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 13HODE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4881.23" spread="11979.79"/>
                    <measurement group_id="O2" value="2308.05" spread="4654.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 9HODE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="729.38" spread="1789.68"/>
                    <measurement group_id="O2" value="335.48" spread="643.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 15HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.99" spread="28.41"/>
                    <measurement group_id="O2" value="28.12" spread="79.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 12HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.05" spread="11.37"/>
                    <measurement group_id="O2" value="7.87" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal breast tissue 5HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" spread="4.47"/>
                    <measurement group_id="O2" value="84.07" spread="354.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast tissue PGE2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328.12" spread="884.633"/>
                    <measurement group_id="O2" value="81.15" spread="181.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast tissue PGD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335.88" spread="894.77"/>
                    <measurement group_id="O2" value="92.01" spread="184.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast tissue 20HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.52" spread="44.5"/>
                    <measurement group_id="O2" value="11.49" spread="48.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast tissue 13HODE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4584.87" spread="10465.02"/>
                    <measurement group_id="O2" value="2343.46" spread="4379.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast tissue 9HODE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="694.78" spread="1611.17"/>
                    <measurement group_id="O2" value="350.07" spread="655.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast tissue 15HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.11" spread="199.85"/>
                    <measurement group_id="O2" value="95.85" spread="190.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast tissue 12HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.17" spread="233.57"/>
                    <measurement group_id="O2" value="14.52" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant breast tissue 5HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="21.91"/>
                    <measurement group_id="O2" value="5.74" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in PGE2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319" spread="868.1"/>
                    <measurement group_id="O2" value="80" spread="182.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in PGD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.4" spread="896.4"/>
                    <measurement group_id="O2" value="89.7" spread="185.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in 20HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="45.4"/>
                    <measurement group_id="O2" value="7.3" spread="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in 13HODE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-296.4" spread="4812.1"/>
                    <measurement group_id="O2" value="35.4" spread="4412.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in 9HODE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.6" spread="761.9"/>
                    <measurement group_id="O2" value="14.6" spread="673.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in 15HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" spread="191.4"/>
                    <measurement group_id="O2" value="67.7" spread="210.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in 12HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" spread="229.4"/>
                    <measurement group_id="O2" value="6.7" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in 5HETE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="19.6"/>
                    <measurement group_id="O2" value="-78.3" spread="355.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days to Establish Difference in Proliferation in Malignant Breast Tissue</title>
        <description>ANOVA will be used to assess the effect of the supplementation in malignant breast tissue with less proliferation in malignant breast tissue in comparison to women who took the placebo.</description>
        <time_frame>At time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Omega-3 Fatty Acid)</title>
            <description>Patients receive omega-3 fatty acid PO daily for 7-14 days.
omega-3 fatty acid: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO daily for 7-14 days.
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days to Establish Difference in Proliferation in Malignant Breast Tissue</title>
          <description>ANOVA will be used to assess the effect of the supplementation in malignant breast tissue with less proliferation in malignant breast tissue in comparison to women who took the placebo.</description>
          <units>Days on treatment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" spread="16.6"/>
                    <measurement group_id="O2" value="24.2" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days to Establish Increased Apoptosis in Malignant Breast Tissue</title>
        <description>ANOVA will be used to assess the effect of the supplementation in malignant breast tissue with greater apoptosis in malignant breast tissue in comparison to women who took the placebo.</description>
        <time_frame>At time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Omega-3 Fatty Acid)</title>
            <description>Patients receive omega-3 fatty acid PO daily for 7-14 days.
omega-3 fatty acid: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO daily for 7-14 days.
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days to Establish Increased Apoptosis in Malignant Breast Tissue</title>
          <description>ANOVA will be used to assess the effect of the supplementation in malignant breast tissue with greater apoptosis in malignant breast tissue in comparison to women who took the placebo.</description>
          <units>Days on treatment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.2"/>
                    <measurement group_id="O2" value="3.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14-21 days after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Omega-3 Fatty Acid)</title>
          <description>Patients receive omega-3 fatty acid PO daily for 7-14 days.
omega-3 fatty acid: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO daily for 7-14 days.
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward Levine, MD</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>336-716-5440</phone>
      <email>elevine@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

